Neurochem to start Phase II/III study

Neurochem (TSE:NRM) said it will begin in the next few weeks a pivotal 150-patient U.S. Phase II/III study of Fibrillex, an oral small molecule inhibitor of amyloid fiber formation, to treat secondary...